Decision Analysis: Commercializing Anti-Vascular Endothelial Growth Factor Monoclonal Antibody or Implantable Medical Device
|
|
- Reginald Gilbert
- 7 years ago
- Views:
Transcription
1 4 Decision Analysis: Commercializing Anti-Vascular Endothelial Growth Factor Monoclonal Antibody or Implantable Medical Device BRIAN NEMAN Master of Health Administration Candidate, 2010 University of Southern California School of Policy, Planning, and Development Drug/medical device development requires detailed planning and analysis because the commercialization process is time consuming, capital intensive, and highly regulated by the FDA. Therefore, Decision Analysis 1 was used to determine the best alternative for SCLERA LLC, the proposed client of this decision analysis for purposes of this assignment. SCLERA LLC has the potential to launch either an anti-vegf (Vascular Endothelial Growth Factor) monoclonal antibody designed to treat Age-related Macular Degeneration (AMD), or a sustained-release extraoccular drug delivery device designed for the delivery of these anti-vegf therapies into the eye, in order to treat the same disease. All research completed for this article was conducted for purposes of coursework, and not on behalf of SCLERA LLC. University of Southern California School of Policy Planning and Development
2 INTRODUCTION Although commercializing a monoclonal antibody would result in a higher payoff than launching a medical device, adjusting for outcome probabilities and costs, choosing to commercialize a medical device by first applying for Class I/Class II certification, is a better decision than choosing to launch either an anti-vegf monoclonal antibody, or a medical device by first applying for Class III certification. Class I/Class II medical devices require lower requirements for review and approval than do Class III devices. Devices are classified as Class I/II if they are substantially equivalent to existing devices. Substantial equivalence is defined as having the same use and technological characteristics as an existing approved device. To earn approval, a 510k pre-market notification (PMA) must be filed, asking the FDA to certify the device as Class I/II. This process is usually completed over 3-6 months 2. On the other hand, however, Class III medical devices require higher levels of critique and observation than do Class I/II medical devices. The applicant must file an Investigational Device Exemption (IDE) to earn permission to perform human trials. Assuming that the clinical trials yield favorable results, a PMA may be filed to allow for marketing of the device. 2 THE PROBLEM & ALTERNATIVES Corinne G. Wong, PhD. is the owner, principal, and Chief Scientific Officer (CSO) of a contract research organization, SCLERA LLC. Therefore, she is the sole decision-maker of her company. Dr. Wong has the ability to commercialize two products, but can only commercialize one, due to her time constraints. Therefore, she is looking to launch the product that has the best payoff, relative to risks and costs, over a five year period. The payoff over a five year period was chosen because SCLERA LLC assumes that it will be acquired by a larger biotechnology or medical device company after it has proven successful in that time period. 3,4 The first product is a therapeutic agent, an anti-vegf antibody that targets the blood vessels of patients with Age-related Macular Degeneration (AMD). Anti-VEGF antibodies are used to reverse the detrimental effects of AMD. Genentech Inc. has already captured over 88% of the AMD market share with its product, Lucentis, because of its superiority. However, Lucentis is not infallible. The price of the product is very expensive at $2,000 per injection, which must be injected once/month. In fact, Genentech Inc. notes that another one of its products, Avastin, a much cheaper ($100/injection) biochemical cousin of Lucentis, is stealing revenue away from Lucentis. 5 Therefore, there is a need in the market for a much cheaper product, and SCLERA LLC has the ability to meet that demand. In effect, the payoff of commercializing a therapeutic agent is much higher than that of commercializing a medical device ($233,119,150 for the therapeutic compared to $12,695,438 and $6,702,913 for a Class III medical device and a Class I/Class II medical device, respectively). 5,7 However, as lucrative as this opportunity may seem, the financial risks are higher and the probability of success is much lower than if SCLERA LLC was to launch a medical device. For instance, preclinical trials and patenting of the therapeutic agent costs $1,000,000, with only a 80% chance of approval by the FDA. 3,4 Furthermore, the cost of conducting Phase I clinical trials is $14,610,000, with only a 75% chance of approval. 1,2 Moreover, Phase II clinical trials are riskier and more expensive than Phase I clinical trials; Phase II trials cost $39.35 million, with only a 50% chance of FDA approval. 1,2 Finally, Phase III clinical trials are just as risky as Phase I clinical trials at a 75% chance of FDA approval, but are seven times as expensive, costing $98,310,000. 1,2 Additionally, there are many potential competitors that will come to market within the next few years that are much stronger, scientifically, financially, operationally, and managerially, than SCLERA LLC. 6
3 On the other hand, the second product is a sustained-release drug delivery device designed for Lucentis, Genentech s AMD product, and other potential AMD products. SCLERA LLC will charge $200 for the device that will release Lucentis or other anti-vegf therapies into the eye, over a period of eight months. Therefore, for only $300/year ($200/8 months) and the cost of 1.5 injections of Lucentis, a patient can observe the same effects as those of eight injections of Lucentis. Thus, the patient saves nearly $21,000/year. Not surprisingly, the Center for Medicare and Medicaid Services (CMS) will adopt this immediately because it is responsible for 80% of the cost of Lucentis. Although this device will reduce health care expenditures, the payoff to SCLERA LLC is much lower than that of a therapeutic agent ($233,119,150 for the therapeutic compared to $12,695,438 and $6,702,913 for a Class III medical device and a Class I or II medical device, respectively). 5,7 However, the financial risk and probability of failure is lower for a device than it is for a therapeutic ($-400,000 for a Class I/Class II medical device, $-1,900,000 for a Class III medical device and $-153,000,000 for a therapeutic). When selecting to commercialize the medical device, SCLERA LLC has the option to choose to apply for Class I/Class II certification or Class III certification. Class I/Class II certification is given to those devices that pose less risk to patients, and thus require less oversight by the FDA. 9 introduce this concept earlier Class III medical devices, on the other hand, are riskier to the patient, and require more oversight than Class I/Class II medical devices. Class I/Class II certification may be granted by the FDA to SCLERA LLC only in the case that there is another medical device in the marketplace that has already been certified by the FDA as a Class I/Class II product. In fact, there is a product on the market that resembles SCLERA LLC s sustained-release drug delivery device. If SCLERA LLC chooses to apply for Class I/Class II certification, it must pass the Substantial Equivalence (SE) test. This test measures whether or not SCLERA LLC s product closely resembles that which is in the market already. The FDA has reported that the approval rate for products that apply for Class I/Class II medical devices is 90%. 9 The benefits of applying for Class I/Class II certification are that the FDA approval process only requires the filing of a FDA 510(k) document, and not the Pre-Market Approval application (PMA). 9 Therefore, SCLERA LLC is not required to conduct clinical trials that demonstrate the safety of the medical device. In essence, SCLERA LLC must only conduct preclinical trials. The drawbacks of Class I/Class II certification are that other competitors may enter the marketplace relatively easily because they only need to file an FDA 510(k) and conduct preclinical trials, which are relatively cheap, and show Substantial Equivalence to SCLERA LLC s medical device. Therefore, the costs for commercializing a Class I/Class II medical device are $400,000, and the probability of approval is 90%. 3,4,9 On the other hand, the payoff is $6,702, This payoff is much lower than that of a Class III medical device, because the barrier of entry for competitors is much lower than it would be if SCLERA LLC s medical device was Class III certified. The benefit of Class III certification is that a competitor must file a FDA 510(k) and then a PMA, and conduct clinical trials before it is granted approval to commercialize its product. Completing a PMA is riskier, and requires much more time and energy than completing a FDA 510(k), alone. 9 Therefore, SCLERA LLC may enjoy market exclusivity and a high barrier to entry, which is reflected in its revenues of $12,695, However, the drawbacks to obtaining Class III certification instead of Class I/Class II certification are that approval is much riskier (90% approval of Class I/Class II, and 67% for Class III medical devices and a subsequent 78% for PMAs for those Class III medical devices) and more stringent (FDA 510(k) for Class I/Class II, and FDA 510(k) and a PMA for Class III), and that commercializing is more financially burdensome ($-400,000 for Class I/Class II, and $-1,500,000 for Class III). The results describe how decision analysis was critical to evaluating the best alternative for SCLERA LLC.
4 RESULTS Decision analysis suggests that SCLERA LLC would earn a better payoff by choosing to commercialize a Class I/Class II medical device than by choosing to commercialize a Class III medical device or a therapeutic agent. The reasoning behind the decision is that although there is potential for market penetration by competitors, the probability of success (90% approval) is substantially higher than that for a Class III medical device (67% for FDA 510(k) for Class III and a subsequent 78% for PMA approval). Additionally, in the case that SCLERA LLC s medical device does not obtain Class I/Class II certification on its first attempt, it has two options. Primarily, it may file a de Novo Petition (not demonstrated in the decision analysis due to lack of probability/statistical information) that challenges the FDA s decision. On the other hand, SCLERA LLC may also opt to file a FDA 510(k) for Class III certification. Therefore, the payoff for choosing to apply for FDA 510(k) Class I/Class II certification is higher, $6,568,785, than choosing to apply for FDA 510(k) Class III certification, $5,361,636. On the other hand, the payoff for choosing to apply for FDA 510 Class I/Class II certification is higher, $6,568,785, than that for choosing to commercialize the anti-vegf therapeutic, $6,470,809. The reasoning for this is that although the payoff after the completion of Phase III clinical trials is $233,119,150, after adjusting for the costs of preclinical and clinical trials ($153,000,000) and the probabilities of outcomes at each level (preclinical-80%, Phase I-75%, Phase II-50%, Phase III-75%), commercializing a medical device and applying for Class I/Class II certification is a better option for SCLERA LLC. However, since the difference between the two outcomes is less than $100,000 ($6,568,785-$6,470,809), if SCLERA LLC were to negotiate a higher up-front offer from an established pharmaceutical/biotechnology company (Licensee) to sell SCLERA LLC s product (Licensor), the better decision may be to commercialize a therapeutic agent. RELEVANCE OF DECISION ANALYSIS Decision Analysis was used to measure the payoff for the alternatives outlined above. This analytical tool has much relevance to the pharmaceutical/biotechnology/medical device industry, as it has been used in the past by many pharmaceutical companies, including Bayer Pharmaceuticals. 2 Because drug development is time consuming, capital intensive, risky, and highly regulated by the FDA, companies in this industry use decision analysis as opposed to intuition alone. In fact, Decision Analysis is used to determine the feasibility and market potential of each of a company s product candidates. 2 Data, including statistics, financial data regarding clinical trials, and outcome probabilities are collected at each level of development in order to get the most precise value for each alternative. Outcome probabilities, costs of each step in the commercialization process and the payoff of each alternative required extensive research and referencing of 10-K reports of relevant companies, primary sources such as interviews with industry experts, and data from publications within the pharmaceutical/biotechnology/medical device industry. Since each step of the clinical trials process has its own cost or payoff, and is contingent on the success/approval of the previous step, Decision Analysis is a valuable tool used to determine the value of each alternative. VALIDITY, ASSUMPTIONS and LIMITATIONS Although the recommended solution may seem feasible and logical, there are many uncertainties that challenge its credibility. For instance, the costs of clinical trials for the therapeutic are an average of all those completed to date. i There was no access to Regeneron Pharmaceuticals Inc. s clinical trials costs, which would have given a more precise estimate of SCLERA LLC s costs of conducting clinical trials. The
5 reason is that the costs of the test drug and the control drug are similar to those which SCLERA LLC would use in its clinical trial. On the other hand, the probabilities of the outcomes associated with each phase of the clinical trial process are also subject to inaccuracy. ii The propriety nature of the product precludes access to the FDA s data on the outcomes of clinical trials for anti-vegf therapies, then the probabilities for each phase of the clinical trial process would be more precise. Additionally, the costs and probabilities of approval and disapproval of the results of pre-clinical trials (In Vitro/In Vivo) for the therapeutic agent are estimates by expert scientist, Dr. Corinne Wong, and veteran venture capitalist, Dr. Frederick Haney. iii,iv Most importantly, the outcomes/payoffs for the approval of the therapeutic are based on many assumptions. Primarily, the market size assumes a 10% compounded annual growth rate. This assumption is based on the evidence provided by the increase in sales of Lucentis, Genentech Inc. s drug that for AMD treatment. v This rate also assumes the possibility of the entry of competitors in this market place. The entry of competitors is also reflected in the market share of the licensee (the company that which SCLERA LLC chooses to license its therapeutic agent). vi However, the % of revenue due to SCLERA LLC is quite accurate, as shares of revenue are usually in the 5-10% range. 5 Finally, the payoff for the therapeutic agent also assumes that the pharmaceutical/biotechnology company to which SCLERA LLC will license its product, will pay an up-front cash payment of $180,000, This was assumed because it was the amount of money given to Regeneron Pharmaceuticals, Inc. by Bayer Pharmaceuticals, Inc. upon FDA clearance. vii Moreover, there are also limitations to the credibility of the probabilities and outcomes/payoffs for the commercialization of the medical device. For example, the payoff for class III approval by the FDA is contingent on a few assumptions. The number of patients in the market, which is critical in indicating revenue from the device, was based on the market size of the respective year. The number of patients in the market was calculated by dividing the market size for the given year by $24,000. The reason for this is that each patient spends $24,000/year on Lucentis ($2,000/month), and it comprises over 88% of the market share. Since SCLERA LLC will choose to distribute this product itself, it will not require any licensing. However, the market penetration rate assumes that barriers to entry of a competitor or a similar product will be very high. With SCLERA LLC s device as a Class III product, competitors would need to file Pre-Market Applications (PMAs) and spend roughly $1,500,000 on clinical trials before they enter the market place. 3,4 This barrier to entry is reflected in SCLERA LLC s market penetration rate over the first five years of commercializing the product. This rate was a rough estimate based on the idea that the Center for Medicare and Medicaid Services (CMS) would adopt the product in order to save the money that it was spending every month to treat AMD patients. On the other hand, if SCLERA LLC was to issue its product as a Class I or Class II medical device, then the barriers to entry would be low. In this case, a competitor would need only to file the FDA 510(k) document, which takes less time to be completed and approved than would the PMA. viii Competitors would only need to show Substantial Equivalence (SE) to a Class I or Class II medical device before it is commercialized. ix The market penetration rate given that SCLERA s product is a Class I/Class II medical device reflects the fact that competitors will enter the market in 2011 (year 3). This estimate is rough, and is subject to high variance. However, in the case of a Class I/Class II or a Class III medical device, the probabilities are very accurate, as they were obtained from the U.S. Government Accountability office. 9
6 DATA APPENDIX istonebraker, Jeffrey S. "How Bayer Makes Decisions to Develop New Drugs." INTERFACES 32 (2002): ii DiMasi, Joseph A., Ronald W. Hansen, and Henry G. Grabowski. "The price of innovation: new estimates of drug development costs." Journal of Health Economics 22 (2003): iii "Interview with Dr. Fred Haney." Telephone interview. 1 Apr iv "Interview with Dr. Corinne Wong." Telephone interview. 2 Apr v Genentech 10-K report. vi Waltz, Emily. "Companies eye slice of age-related macular degeneration market." Nature Biotechnology 24 (2006): vii Regeneron Pharmaceuticals Inc. 10-K report. viii ix United States. United States Accountability Office. Medical Devices: FDA Should Take Steps to Ensure That High-Risk Device Types Are Approved through the Most Stringent Premarket Review Process. Government Accountability Office, The majority of the sources above have been reviewed by the Securities and Exchange Commission (SEC). Additionally, the data on outcome probabilities associated with each stage of the trial are also accurate. On the other hand, clinical trial costs are reliable, but subject to little variance due to the fact that they were evaluated in terms of dollars in the year However, these costs were adjusted for inflation. The interviews with Dr. Fred Haney and Dr. Corinne Wong are also subject to possible variance due to the fact they are expert opinions.
Ohr Pharmaceutical Reports Fiscal Year 2015 Financial and Business Results
December 10, 2015 Ohr Pharmaceutical Reports Fiscal Year 2015 Financial and Business Results OHR-102 Phase 3 Program in Wet-AMD to be Initiated Upon Completion of SPA; Enroll Patients in Q1 2016 Conference
More informationCTC Technology Readiness Levels
CTC Technology Readiness Levels Readiness: Software Development (Adapted from CECOM s Software Technology Readiness Levels) Level 1: Basic principles observed and reported. Lowest level of software readiness.
More informationTERM SHEET EXAMPLE. 1 P age
1 P age TERM SHEET EXAMPLE BIOTECHCO Overview & Business Strategy BIOTECHCO (the licensor), located in North Dakota, has a proprietary technology called ZIP that can generate fully human antibodies with
More informationPeptide and Sustained Release Technology to Treat Ocular Diseases and Cancer
Peptide and Sustained Release Technology to Treat Ocular Diseases and Cancer Jordan Green, PhD, Co-Founder and CEO Wendy Perrow, MBA, Senior Business Advisor February 11, 2015 www.asclepix.com Advantages
More informationThe Commercialization of Technology Concepts into Medical Products
The Commercialization of Technology Concepts into Medical Products Kevin J. Scanlon, Ph.D. New Zealand 2006 International BioScience Overview Pharmaceutical Industry Biotechnology Startups Investment Community
More informationDiabetes & blindness. due to DME BLINDNESS IN EUROPE
Diabetes & blindness due to DME BLINDNESS IN EUROPE Blindness is a life-changing disability which puts a heavy strain on the daily lives of sufferers, their families, and society at large. Today, 284 million
More informationUNLEASHING THE NEXT GENERATION OF BIOTECHNOLOGY INNOVATION
UNLEASHING THE NEXT GENERATION OF BIOTECHNOLOGY INNOVATION Modern biotechnology is a young industry. But in just over four decades, the scientists, researchers and entrepreneurs working in this field have
More informationA PERSONAL BUDGETS OPTIONS & PROCESS INFORMATION FOR PROVIDERS
A PERSONAL BUDGETS OPTIONS & PROCESS INFORMATION FOR PROVIDERS People who are eligible for social care services will be allocated a Personal Budget the amount of money available to spend on meeting their
More informationico Therapeutics Inc. Condensed Interim Financial Statements (Unaudited) September 30, 2012 and 2011 (in Canadian dollars)
Condensed Interim Financial Statements (Unaudited) September 30, 2012 and 2011 Balance Sheet (Unaudited) Assets Note September 30, 2012 December 31, 2011 Current assets Cash and cash equivalents 1,478,167
More informationU.S. Contract Research Outsourcing Market: Trends, Challenges and Competition in the New Decade. N8B7-52 December 2010
U.S. Contract Research Outsourcing Market: Trends, Challenges and Competition in the New Decade December 2010 Table of Contents Notes on Methodology 8 Market Introduction and Segmentation Introduction
More informationStrategic Licensing in the New Economy
Strategic Licensing in the New Economy Dennis Fernandez Fernandez & Associates LLP 1047 El Camino Real, Ste 201 Menlo Park, CA 94025 dennis@iploft.com Charles R. Neuenschwander Patent Solutions LP 5420
More informationClinical trials for medical devices: FDA and the IDE process
Clinical trials for medical devices: FDA and the IDE process Owen Faris, Ph.D. Deputy Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health,
More informationAvastin (Bevacizumab) Intravitreal Injection
Avastin (Bevacizumab) Intravitreal Injection This handout describes how Avastin may be used to treat wet age related macular degeneration (AMD) or macular edema due to retinal vascular disease such as
More informationBreakthrough oral drug delivery technology for diabetes, drugs and vaccines November 5, 2014
Oramed Pharmaceuticals, Inc. Initiating Report Breakthrough oral drug delivery technology for diabetes, drugs and vaccines November 5, 2014 Key data Sector Rating Biotechnology BUY Target Price $45.00
More informationWhy Are Drugs So Expensive? Learning About the Drug Development Process
Why Are Drugs So Expensive? Page 1 of 92 Why Are Drugs So Expensive? Learning About the Drug Development Process written by: Ann Newman Seventh Street Development Group This product is for your Personal
More informationUNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationA 2014 Update of Cost Savings and Marketplace Analysis of the Health Care Group Purchasing Industry
A 2014 Update of Cost and Marketplace Analysis of the Health Care Group Purchasing Industry Dobson DaVanzo & Associates, LLC Vienna, VA 703.260.1760 www.dobsondavanzo.com A 2014 Update of Cost and Marketplace
More informationTaking Strategic Partnerships to the Next Level: An Alternative Approach to Licensing Your Development Asset
Taking Strategic Partnerships to the Next Level: An Alternative Approach to Licensing Your Development Asset Introduction In this era of strategic development deals, inventiv Health has significantly broadened
More informationCost of Developing a New Drug
Tufts Center for the Study of Drug Development Briefing Cost of Developing a New Drug November 18, 2014 E-mail: csdd@tufts.edu Twitter: @TuftsCSDD #TuftsCostStudy Phone: 617-636-2170 Innovation in the
More informationGAO NEW DRUG DEVELOPMENT. Science, Business, Regulatory, and Intellectual Property Issues Cited as Hampering Drug Development Efforts
GAO United States Government Accountability Office Report to Congressional Requesters November 2006 NEW DRUG DEVELOPMENT Science, Business, Regulatory, and Intellectual Property Issues Cited as Hampering
More informationFRC Risk Reporting Requirements Working Party Case Study (Pharmaceutical Industry)
FRC Risk Reporting Requirements Working Party Case Study (Pharmaceutical Industry) 1 Contents Executive Summary... 3 Background and Scope... 3 Company Background and Highlights... 3 Sample Risk Register...
More informationSchneps, Leila; Colmez, Coralie. Math on Trial : How Numbers Get Used and Abused in the Courtroom. New York, NY, USA: Basic Books, 2013. p i.
New York, NY, USA: Basic Books, 2013. p i. http://site.ebrary.com/lib/mcgill/doc?id=10665296&ppg=2 New York, NY, USA: Basic Books, 2013. p ii. http://site.ebrary.com/lib/mcgill/doc?id=10665296&ppg=3 New
More informationSPHERIX INCORPORATED (Exact name of registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationFDA approves Lucentis (ranibizumab injection) for treatment of diabetic macular edema
Media Release Basel, 13 August 2012 FDA approves Lucentis (ranibizumab injection) for treatment of diabetic macular edema First major treatment advance in more than 25 years for sight-threatening condition
More informationPROMETIC LIFE SCIENCES INC.
PROMETIC LIFE SCIENCES INC. Investor Update July to September 2002 This present release must be considered as the quarterly report to shareholders. 1. Letter to Shareholders Dated November 21, 2002 2.
More informationOverview of Drug Development: the Regulatory Process
Overview of Drug Development: the Regulatory Process Roger D. Nolan, PhD Director, Project Operations Calvert Research Institute November, 2006 Adapted from course taught by Cato Research Background: Roger
More informationMarch 2, 2015. Manon Ress, PhD The Union for Affordable Cancer Treatment (UACT) 1621 Connecticut Avenue, N.W. Washington, D.C. 20006. Dear Dr.
March 2, 2015 Manon Ress, PhD The Union for Affordable Cancer Treatment (UACT) 1621 Connecticut Avenue, N.W. Washington, D.C. 20006 Dear Dr. Ress: Thank you for your letter of February 3, 2015 regarding
More informationIP Valuation. WIPO Workshop on Innovation, Intellectual Asset Management and Successful Technology Licensing: Wealth Creation in the Arab Region
IP Valuation WIPO Workshop on Innovation, Intellectual Asset Management and Successful Technology Licensing: Wealth Creation in the Arab Region Muscat, Oman, December 12 and 13, 2011 Topics Intangibles
More informationA: SGEAX C: SGECX I: SGEIX
A: SGEAX C: SGECX I: SGEIX NOT FDIC INSURED MAY LOSE VALUE NO BANK GUARANTEE Salient Global Equity Fund The investment objective of the Salient Global Equity Fund (the Fund ) is to seek long term capital
More informationSuccessful Collaboration Profiles
Successful Collaboration Profiles Underwritten by: Cincinnati USA Partnership for Economic Development and Wood Herron & Evans LLP CTI CLINICAL TRIAL AND CONSULTING SERVICES Stromedix, Inc., a Cambridge,
More informationVIII. FORM 990, SCHEDULE H, HOSPITALS
VIII. FORM 990, SCHEDULE H, HOSPITALS A. Overview of Schedule H, Hospitals Form 990, Schedule H, Hospitals, will be used beginning with 2008 tax years to report information by an organization that operates
More informationValuation of Your Early Drug Candidate. By Linda Pullan, Ph.D. www.sharevault.com. Toll-free USA 800-380-7652 Worldwide 1-408-717-4955
Valuation of Your Early Drug Candidate By Linda Pullan, Ph.D. www.sharevault.com Toll-free USA 800-380-7652 Worldwide 1-408-717-4955 ShareVault is a registered trademark of Pandesa Corporation dba ShareVault
More informationRD LEGAL FUNDING SMARTER MONEY FOR GROWTH. Legal Funding 101
1 Legal Funding 101 Joseph Genovesi, President of RD Legal Funding gives a brief synopsis of the legal funding industry. In this white paper, the reader will gain a basic understanding of a few methods
More informationMergers & acquisitions a snapshot Change the way you think about tomorrow s deals
Mergers & acquisitions a snapshot Change the way you think about tomorrow s deals Stay ahead of the accounting and reporting standards for M&A 1 April 23, 2013 What's inside IPR&D accounting the basics...
More informationUniversity of Minnesota Start-up Guide
University of Minnesota Start-up Guide Office for Technology Commercialization (OTC) - Venture Center A guide for faculty, staff, and entrepreneurs interested in starting a new business based on University
More informationReducing Waste with an Efficient Medicare Prescription Drug Benefit
Issue Brief January 2013 Reducing Waste with an Efficient Medicare Prescription Drug Benefit BY DEAN BAKER* When Congress was debating the Medicare drug benefit in 2003, there were many who advocated that
More informationStructured Debt Finance for Healthcare Companies: How Has it Changed the Lending Landscape?
Structured Debt Finance for Healthcare Companies: How Has it Changed the Lending Landscape? Note: For the purposes of this paper, we will define healthcare as life sciences/biotech, medical devices, diagnostics
More informationBioPharmaceutical Royalty Rates & Deal Terms Report. Licensing Executives Society (U.S.A. & Canada), Inc.
BioPharmaceutical Royalty Rates & Deal Terms Report Licensing Executives Society (U.S.A. & Canada), Inc. June 2008 Table of Contents Introductory Letter 1 LES Survey Committee 2 Introduction 3 Report Highlights
More informationTECHNOLOGY TRANSFER FINANCING OPPORTUNITIES AND LIMITS IN EUROPEAN UNION
156 Finance Challenges of the Future TECHNOLOGY TRANSFER FINANCING OPPORTUNITIES AND LIMITS IN EUROPEAN UNION Assoc. Prof. Laura GIURCĂ VASILESCU, PhD Ec. Maria BUŞE Nicoleta DRĂCEA, PhD student University
More informationAFFITECH and XOMA Sign Antibody Collaboration and Cross-License Agreement
FOR IMMEDIATE RELEASE Ref 05AFF05 Contacts for Affitech: Contacts for XOMA Affitech (Norway): Investor Inquiries Dr. Martin Welschof Ellen M Martin Chief Executive Officer Kureczka/Martin Associates Phone:
More informationAge- Related Macular Degeneration
Age- Related Macular Degeneration Age-Related Macular Degeneration (AMD) is the leading cause of blindness in the United States. It is caused by damage to a localized area of the central retina called
More informationexactly. The need for efficiency in developing effective new therapeutics has never been greater.
exactly. The need for efficiency in developing effective new therapeutics has never been greater. As demands on the global healthcare system increase and treating disease becomes more complex, the research,
More informationTHE LONG-TERM CARE PARTNERSHIP PROGRAM
A Guide to Long-Term Care for State Policy Makers THE LONG-TERM CARE PARTNERSHIP PROGRAM Financing the increasing demand for long-term care services will be a significant 21 st century challenge. A key
More informationDiscover more, discover faster. High performance, flexible NLP-based text mining for life sciences
Discover more, discover faster. High performance, flexible NLP-based text mining for life sciences It s not information overload, it s filter failure. Clay Shirky Life Sciences organizations face the challenge
More informationCALIFORNIA DEPARTMENT OF HEALTH CARE SERVICES UTILIZATION MANAGEMENT DIVISION PUBLIC HOSPITAL PROJECT
CALIFORNIA DEPARTMENT OF HEALTH CARE SERVICES UTILIZATION MANAGEMENT DIVISION PUBLIC HOSPITAL PROJECT External Stakeholders Workgroup Teleconference * March 25, 2013 Teleconference Minutes - DRAFT * Please
More informationCompany Presentation
Company Presentation DISCLAIMER This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and asset situation of amp biosimilars
More informationCall 2014: High throughput screening of therapeutic molecules and rare diseases
Call 2014: High throughput screening of therapeutic molecules and rare diseases The second call High throughput screening of therapeutic molecules and rare diseases launched by the French Foundation for
More informationAssociate Group Director, Regulatory Intelligence & Policy
Date: 06/24/16 Associate Group Director, Regulatory Intelligence & Policy Job ID: 2974410847 Job Function Project Management Regulatory Affairs Location United States - District of Columbia Washington
More informationOMT, Inc. Acquisition Conference Call December 17, 2015 NASDAQ: LGND
OMT, Inc. Acquisition Conference Call December 17, 2015 NASDAQ: LGND Safe Harbor Statement The following presentation contains forward-looking statements regarding Ligand s prospects, plans and strategies,
More informationDiscount rates in drug development
Discount rates in drug development When valuing a biotech company with a discounted cash flows approach (NPV or rnpv), the value is notoriously sensitive to the discount rate. But unfortunately, the standard
More informationA Primer on Long-term Care Insurance
A Primer on Long-term Care Insurance What Is It? Long-term care insurance (LTCi) provides a daily financial benefit to cover the cost of long-term custodial care (LTC) for those who are unable to take
More informationAdjudication in Oncology Trials: A Concept Whose Time Has Come
Adjudication in Oncology Trials: A Concept Whose Time Has Come By WorldCare Clinical: Richard Walovitch, PhD, Chief Medical Officer, Asli Memisoglu, ScD, Director of Biostatistics and Data Management,
More informationBOOSTING THE COMMERCIAL RETURNS FROM RESEARCH
BOOSTING THE COMMERCIAL RETURNS FROM RESEARCH Submission in response to the Discussion Paper November 2014 Page 1 ABOUT RESEARCH AUSTRALIA is an alliance of 160 members and supporters advocating for health
More information21st Century Cures Act: Key Provisions Related to Medical Devices
21st Century Cures Act: Key Provisions Related to Medical Devices July 30, 2015 Food & Drug The 21st Century Cures Act ( the Act or HR 6 ) was passed by the House of Representatives on July 10, 2015, by
More informationA Product and Pipeline Analysis of the Multiple Sclerosis Therapeutics Market
A Product and Pipeline Analysis of the Multiple Sclerosis Therapeutics Market Launch of Several Pipeline Oral Products Could Diminish the Market for Injectable Therapies NEC3-52 November 2014 Contents
More informationEnergizing Innovation. By Kazem Kazempour, PhD, George Steinfels, PhD, MBA and Mukesh Kumar, PhD, RAC
Energizing Innovation By Kazem Kazempour, PhD, George Steinfels, PhD, MBA and Mukesh Kumar, PhD, RAC Former UK Prime Minister Harold Macmillan once said, to be alive at all involves some risk. This statement
More informationIP Strategy for Drug Discovery: A Dedicated Research Firm s Perspective
Journal of Intellectual Property Rights Vol 17, September 2012, pp 478-483 IP Strategy for Drug Discovery: A Dedicated Research Firm s Perspective Vinita Radhakrishnan Connexios Life Sciences, 49, Shilpa
More informationGoizueta Healthcare Forum 2011 Leadership in Healthcare Forum February 10 th - 11 th, 2011
Goizueta Healthcare Forum 2011 Leadership in Healthcare Forum February 10 th - 11 th, 2011 Schedule of Events February 10 th 6:30-7:15pm: Opening Address: Scott Lloyd, Co-Founder and President of Extrakare,
More informationCancer Drug Reimbursement within the Context of Clinical Trials. (Draft for consultation purposes) Version 8.0
Cancer Drug Reimbursement within the Context of Clinical Trials (Draft for consultation purposes) Version 8.0 May 17, 2013 Introduction Clinical and cost-effectiveness factors have led most public payers
More informationXENOPORT INC FORM 8-K. (Current report filing) Filed 05/08/14 for the Period Ending 05/08/14
XENOPORT INC FORM 8-K (Current report filing) Filed 05/08/14 for the Period Ending 05/08/14 Address 3410 CENTRAL EXPRESSWAY SANTA CLARA, CA 95051 Telephone 4086167200 CIK 0001130591 Symbol XNPT SIC Code
More informationMobile Medical Applications: An Overview of FDA Regulation
Mobile Medical Applications: An Overview of FDA Regulation RAPS Annual Convention 2014 Austin, Texas Michael A. Swit, Esq. Special Counsel, FDA Law Practice Duane Morris LLP Standard Disclaimers The views
More information2. Exercising the option - buying or selling asset by using option. 3. Strike (or exercise) price - price at which asset may be bought or sold
Chapter 21 : Options-1 CHAPTER 21. OPTIONS Contents I. INTRODUCTION BASIC TERMS II. VALUATION OF OPTIONS A. Minimum Values of Options B. Maximum Values of Options C. Determinants of Call Value D. Black-Scholes
More informationThe ROI. of Speech Tuning
The ROI of Speech Tuning Executive Summary: Speech tuning is a process of improving speech applications after they have been deployed by reviewing how users interact with the system and testing changes.
More informationSpecialty Drug Hyperinflation:
Specialty Drug Hyperinflation: The Risk to Patients and the Health Care System Specialty drugs 1 offer important hope for many patients with complex, hard-to-treat illnesses. While the price of specialty
More informationPennino Corporation TECHNOLOGY TO IMPROVE LIFE
Pennino Corporation TECHNOLOGY TO IMPROVE LIFE Agenda The Opportunity Highlights Corporate Profile NYU Relationship Obesity and Diabetes Graphics and Facts Next Stage of Development Efficacy and Safety
More informationWhat is a P-value? Ronald A. Thisted, PhD Departments of Statistics and Health Studies The University of Chicago
What is a P-value? Ronald A. Thisted, PhD Departments of Statistics and Health Studies The University of Chicago 8 June 1998, Corrections 14 February 2010 Abstract Results favoring one treatment over another
More informationRegulation and Access to Innovative Medical Technologies. A comparison of the FDA and EU Approval Processes and their Impact on Patients and Industry
Regulation and Access to Innovative Medical Technologies A comparison of the FDA and EU Approval Processes and their Impact on Patients and Industry June 2012 Regulation and Access to Innovative Medical
More informationAn Introduction to Valuations
An Introduction to Valuations PREPARED FOR ROCKY MOUNTAIN BIOBOOSTER MAY 9 TH, 2012 An ICON plc Company Agenda Introductions Valuation methods When is a valuation appropriate? How do you maximize your
More informationCancer Clinical Trials: In-Depth Information
Cancer Clinical Trials: In-Depth Information The Drug Development and Approval Process 1. Early research and preclinical testing 2. IND application filed with FDA 3. Clinical trials (phases 1, 2, and 3)
More informationMedical Billing and the Advantages of a Novelized Pharmaceutical Program
FOR IMMEDIATE RELEASE Compugen Ltd. Reports Fourth Quarter and Calendar 2015 Results Holon, ISRAEL February 9, 2016 Compugen Ltd. (NASDAQ: CGEN), a leading predictive drug discovery company, today reported
More informationPetitioner, Respondents.
No. 12-416 IN THE Supreme Court of the United States FEDERAL TRADE COMMISSION, Petitioner, v. WATSON PHARMACEUTICALS, INC., et al., Respondents. ON WRIT OF CERTIORARI TO THE UNITED STATES COURT OF APPEALS
More informationusing the fully human ADLib system
Company Research and Analysis Report FISCO Ltd. http://www.fisco.co.jp 伪 伪 Focusing on improving technology to obtain antibodies using the fully human ADLib system (4583) (subsequently, the company ) is
More informationLION BIOTECHNOLOGIES, INC.
LION BIOTECHNOLOGIES, INC. FORM 424B3 (Prospectus filed pursuant to Rule 424(b)(3)) Filed 01/30/14 Address 112 WEST 34TH STREET 17TH FLOOR NEW YORK, NY 10120 Telephone 212-946-4826 CIK 0001425205 Symbol
More informationThe Benefits of Patent Settlements: New Survey Evidence on Factors Affecting Generic Drug Investment
The Benefits of Patent Settlements: New Survey Evidence on Factors Affecting Generic Drug Investment by Bret Dickey 1 Jonathan Orszag 2 July 23, 2013 3 1 Bret Dickey is an Executive Vice President with
More informationMEDICAL DEVICE & DIAGNOSTICS
to Guide Strategic Medical Device and Introduction Medical device and diagnostic makers face myriad challenges when developing a new product, including working within resource and financial constraints,
More informationA Letter from MabVax Therapeutics President and Chief Executive Officer
A Letter from MabVax Therapeutics President and Chief Executive Officer Dear Fellow Stockholder: You have invested in MabVax Therapeutics because you share our passion for finding new therapies for the
More informationAn Informational Guide to CENTRAL RETINAL VEIN OCCLUSION
Science of CRVO www.scienceofcrvo.org An Informational Guide to CENTRAL RETINAL VEIN OCCLUSION This brochure will guide you in understanding CRVO and the treatment options available to prevent vision loss.
More informationConsolidated Financial Statements
STATUTORY BOARD FINANCIAL REPORTING STANDARD SB-FRS 110 Consolidated Financial Statements This standard applies for annual periods beginning on or after 1 January 2013. Earlier application is permitted
More informationAcucela Inc. IR Meeting
Acucela Inc. IR Meeting Tokyo May 20, 2015 Acucela is a clinical-stage biotechnology company that specializes in discovering and developing novel therapeutics to treat and slow the progression of sight-threatening
More informationWaiver to Allow Participation in a Food and Drug Administration Advisory Committee
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Silver Spring MD 20993 Waiver to Allow Participation in a Food and Drug Administration Advisory Committee DATE:
More informationPMAs, 510(k)s, and Advanced IDE Topics
PMAs, 510(k)s, and Advanced IDE Topics Kenneth J. Cavanaugh Jr., Ph.D. Scientific Reviewer Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health kenneth.cavanaugh@fda.hhs.gov
More informationNegotiating the Software License: Eight Tips for the Licensee
Negotiating the Software License: Eight Tips for the Licensee Brian B. Gilbert 1 A software failure can hamstring your client's business. Be sure to build the solutions into the licensing agreement. WITH
More informationStrategy Manager/Sr. Strategy Manager, Tecentriq - Pricing, Contracting, and Distribution (PCD)
Date: 07/08/16 Strategy Manager/Sr. Strategy Manager, Tecentriq - Pricing, Contracting, and Distribution (PCD) Job ID: 2728953633 Job Function Other Sales and Marketing Location United States - California
More informationRetiree Drug Coverage under the MMA: Issues for Public Comment to Maximize Enhancement in Drug Coverage and Reductions in Drug Costs for Retirees
Retiree Drug Coverage under the MMA: Issues for Public Comment to Maximize Enhancement in Drug Coverage and Reductions in Drug Costs for Retirees Discussion Paper: CMS Employer Open Door Forum I. Summary:
More informationThe Impact of Reinsurance on Group Health Plans
Reinsurance and other fees could impact employer health care costs To help offset the cost of coverage expansion and other provisions, the Patient Protection and Affordable Care Act (ACA) imposes a number
More informationAdventist HealthCare, Inc.
IRB POLICY ON HUMAN RESEARCH PROTECTION (HRP) AND GOOD CLINICAL PRACTICE (GCP) TRAINING Collaborative Institutional Training Initiative (CITI) Requirements at Adventist Healthcare, Inc. I. Required Human
More informationComments on the 21 st Century Cures: Digital Health Care
Comments on the 21 st Century Cures: Digital Health Care July 22, 2014 The Pharmaceutical Research and Manufacturers of America (PhRMA) appreciates the opportunity to provide input to the House Energy
More informationCenter for Medicare and Medicaid Innovation
Center for Medicare and Medicaid Innovation Summary: Establishes within the Centers for Medicare and Medicaid Services (CMS) a Center for Medicare & Medicaid Innovation (CMI). The purpose of the Center
More informationVOCABULARY INVESTING Student Worksheet
Vocabulary Worksheet Page 1 Name Period VOCABULARY INVESTING Student Worksheet PRIMARY VOCABULARY 1. Savings: 2. Investments: 3. Investing: 4. Risk: 5. Return: 6. Liquidity: 7. Stocks: 8. Bonds: 9. Mutual
More informationIMPACT FINANCIAL CONSUMER HEALTHCARE ENGAGEMENT. The. (Or, How Easy it Really is to Save Someone a Buck in This Day and Age)
The FINANCIAL IMPACT on CONSUMER ENGAGEMENT in HEALTHCARE (Or, How Easy it Really is to Save Someone a Buck in This Day and Age) How did the State of Kansas find a savings opportunity in excess of 18 million
More informationClinical Trials in Thalassemia Cell and Gene Therapy Grant Award
Clinical Trials in Thalassemia Cell and Gene Therapy Grant Award The Cooley s Anemia Foundation invites national and international applicants to apply for grants to facilitate clinical trials in Cell and
More informationshutterstock.com Interim Management and Strategic Transactions for International Life Science Companies TCG: experienced, connected, proven success
shutterstock.com Interim Management and Strategic Transactions for International Life Science Companies TCG: experienced, connected, proven success Proven success and contacts. Not just talk. TCG is a
More informationPOSITION PAPER. Promotion of off-label use of medicines by European healthcare bodies in indications where authorised medicines are available
POSITION PAPER Promotion of off-label use of medicines by European healthcare bodies in indications where authorised medicines are available EFPIA May 2014 EFPIA represents the pharmaceutical industry
More information15.963 Management Accounting and Control Spring 2007
MIT OpenCourseWare http://ocw.mit.edu 15.963 Management Accounting and Control Spring 2007 For information about citing these materials or our Terms of Use, visit: http://ocw.mit.edu/terms. 15.963 Managerial
More informationChoice of Discount Rate
Choice of Discount Rate Discussion Plan Basic Theory and Practice A common practical approach: WACC = Weighted Average Cost of Capital Look ahead: CAPM = Capital Asset Pricing Model Massachusetts Institute
More informationItaly. Roundtable on: Role of Competition in the Pharmaceutical Sector and its Benefits for Consumers
Seventh United Nations Conference to review the UN Set on Competition Policy Geneva, 6-10 July 2015 Roundtable on: Role of Competition in the Pharmaceutical Sector and its Benefits for Consumers Statement
More informationBYLAWS OF SCIOPEN RESEARCH GROUP, Inc. (a Delaware Non Stock Corporation) ARTICLE I NAME AND OFFICE
BYLAWS OF SCIOPEN RESEARCH GROUP, Inc. (a Delaware Non Stock Corporation) ARTICLE I NAME AND OFFICE Section 1 Name. The name of this corporation is SciOpen Research Group, Inc. (hereinafter referred to
More informationMedical Device Solutions. Battelle. Applied Research Device Development Clinical Research Sustaining Engineering
Medical Device Solutions Battelle Applied Research Device Development Clinical Research Sustaining Engineering 0 2 Overview Applied Research Device Development Clinical Research Sustaining Engineering
More informationIMMUNOMEDICS, 300 The American Road, Morris Plains, New Jersey 07950 (973) 605-8200 Fax (973) 605-8282
IMMUNOMEDICS, INC. 300 The American Road, Morris Plains, New Jersey 07950 (973) 605-8200 Fax (973) 605-8282 IMMUNOMEDICS ANNOUNCES FIRST QUARTER FISCAL 2014 RESULTS AND CLINICAL PROGRAM DEVELOPMENTS Morris
More information1.3 There have been no material or substantive changes to the Code since last year.
1. Please describe the key components of the GPO s written code of business ethics and conduct. (Please provide a copy and describe any changes since the last submission.) Please assure your response includes:
More information